Leveraging ZEISS Airyscan to integrate subcellular and structural detail with Inscopix functional neural network data

Expanding freely behaving microscopy by delivering increased resolution, signal-to-noise and optical sectioning through data correlation

JENA/Germany, SAN DIEGO/California/USA, 2018-11-05.

At the Annual Meeting of the Society for Neuroscience 2018 (Nov 03 – 07), ZEISS will preview new workflows in collaboration with Inscopix (Palo Alto, CA) where ZEISS’s Airyscan confocal imaging technology is leveraged with the Inscopix freely behaving microscopy systems. The joint workflow development utilizes the increased spatial resolution, signal-to-noise and sectioning of ZEISS Airyscan to further inform the freely behaving signaling data collected with the Inscopix system. The presented workflow will serve as a preview of how the resultant data from the respective systems is correlated to benefit studies in functional neuroscience.

The benefits for scientists

Using Inscopix freely behaving microscopy systems allows researchers to monitor neural signaling during social interactions, addiction, sleep, spatial memory etc. Imaging depth is enhanced through the use of a GRIN lens enabling imaging from both cortical and deep brain areas. The new workflows previewed at Society for Neuroscience 2018 enable correlation of data collected in freely behaving animals with ZEISS Airyscan to provide additional contextual information by through optical sectioning, improved resolution, and improved signal-to-noise. In addition, leveraging the ZEISS Airyscan system allows for the potential of researchers to utilize additional fluorescence labels for structural context as well as potential to correlate with other multimodal imaging (i.e. X-ray microscopy, scanning electron microscopy/focused ion beam).
“The developments at Inscopix to enable co-registration of ZEISS Airyscan data with the large-scale neural activity data in freely moving subjects acquired with Inscopix's platform represents a long-sought marriage of two cornerstone imaging modalities. Integrating subcellular and structural detail with functional neural network data can provide exciting new insights into brain function and dysfunction,” summarized Dr. Kunal Ghosh, CEO of Inscopix.

“The vision is to see the strengths of the Inscopix approach and the ZEISS Airyscan technology combined in an overarching workflow makes us highly excited. We are convinced that joining forces with Inscopix to provide a solution integrating highly relevant functional and structural information is a perfect match”, says Bernhard Zimmermann, Head of the Business Sector Life Sciences at ZEISS Research Microscopy Solutions.

The principle behind ZEISS Airyscan

A traditional confocal microscope scans the sample by illuminating one spot at a time to detect the emitted fluorescence signal. Out-of-focus emission light is rejected at a pinhole. Users can increase image resolution by making the pinhole smaller, but the collected signal drops significantly, since less valuable emission light is passing through.

With ZEISS Airyscan, ZEISS introduced a new detector concept. ZEISS Airyscan is a 32 element area detector. Each detector element functions as a single, very small pinhole, yet the overall assembly covers the area of a large pinhole. Knowing the spatial distribution of each of the 32 detectors results in improved resolution and signal-to-noise. The ZEISS Airyscan detector is available for ZEISS LSM 8 microscope systems and as an upgrade for the ZEISS LSM 710 and ZEISS LSM 780 confocal microscopes.

Press contact

Vybhav Sinha
Carl Zeiss Microscopy GmbH
Phone: +49 3641 64 3949
vybhav .sinha @zeiss .com

Pushkar Joshi
Inscopix Inc.
Phone: +1 (650) 600-3886
pus hkar @inscopix .com


ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. The ZEISS Group develops, produces and distributes measuring technology, microscopes, medical technology, eyeglass lenses, camera and cinema lenses, binoculars and semiconductor manufacturing equipment. With its solutions, the company constantly advances the world of optics and helps shape technological progress. ZEISS is divided up into the four segments Industrial Quality & Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology. The ZEISS Group is represented in more than 40 countries and has over 50 sales and service locations, more than 30 manufacturing sites and about 25 research and development centers around the globe.

In fiscal year 2016/17 the company generated revenue approximating €5.3 billion with around 27,000 employees. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. Carl Zeiss AG is the strategic management holding company that manages the ZEISS Group. The company is wholly owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation).

Further information at

ZEISS Research Microscopy Solutions

ZEISS Research Microscopy Solutions is the world's only one-stop manufacturer of light, electron, X-ray and ion microscope systems and offers solutions for correlative microscopy. The portfolio comprises products and services for the life sciences and materials research as well as for industry, education and clinical practice. The unit is headquartered in Jena. Additional production and development sites are located in Oberkochen, Göttingen and Munich, as well as in Cambridge in the UK, and in Peabody, MA and Pleasanton, CA in the USA. ZEISS Research Microscopy Solutions is allocated to the Industrial Quality & Research segment. Around 6,300 employees work for the segment, generating revenue totaling €1.5 billion in fiscal year 2016/17.

About Inscopix

Inscopix is a discovery phase neuroscience company in Silicon Valley that is focused on advancing the mechanistic understanding of the brain at the level of neural circuits and networks. Inscopix develops miniaturized real-time brain mapping platforms that pave the way for incisive new insights into healthy brain function and for next-generation diagnostics, treatments and therapeutics for brain disorders. Inscopix was recognized as a private-sector partner of the White House BRAIN Initiative in 2014 and by the World Economic Forum as a Technology Pioneer in 2015 and Deloitte’s Technology Fast 500 in 2016.

Further information at